Nanobiose is a specialized company founded in July 2016 near Chambery in France, at the alpine crossroads of Europe.

Our ambition is to propose innovative solutions which improve the in vitro assessment of drug candidates at early stage of development by empowering in vitro assays in more appropriate biological conditions.

Indeed, 90% of drug candidates fail almost at the end of their development when tested on Man, for a lack of efficacy or safety issues, after years of efforts and millions of expenses. Such late failures have a huge impact on pharmaceutical and biotech companies’ economic figures but also on patients, who are still waiting for innovative treatments they need.

In vitro assays are cheap, fast, more ethic than animal studies and at early stages, making them a sweet spot for assays with a high decisional value. But classical in vitro assays lack of performance because of their intrinsic 2D static nature which does not faithfully mimic in vivo conditions. This leads to poorly translatable results from cells to animal then to human and, finally, in delays,  extra costs in the development and a great ‘chance’ of failure.

Therefore, there is an urgent need for innovative in vitro assays which allow researchers to evaluate their drug candidates in conditions mimicking better the human biology.

This allows to make “go / no go” strategic decisions based on relevant efficacy and safety data packages at early stages, with a real impact on development in terms of strategy, costs and time to market.

And at the end, more and safer new medicines for the patients we are.